Docket No.: PF-0420-2 DIV

- 45. An isolated polypeptide selected from the group consisting of:
- a) a polypeptide comprising an amino acid sequence of SEQ ID NO:1,
- b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence of SEQ ID NO:1,
- c) a biologically active fragment of a polypeptide having an amino acid sequence of SEQ ID NO:1, and
- d) an immunogenic fragment of a polypeptide having an amino acid sequence of SEQ ID NO:1.
- 46. (Once Amended) An isolated antibody which specifically binds to a polypeptide comprising a polypeptide selected from the group consisting of:
 - a) a polypeptide having the amino acid sequence of SEQ ID NO:1,
- b) a polypeptide having a naturally occurring amino acid sequence at least 90% identical to the amino acid sequence of SEQ ID NO:1, wherein the polypeptide has nucleotide pyrophosphohydrolase activity,
- c) a fragment of a polypeptide having the amino acid sequence of SEQ ID NO:1, wherein the fragment has nucleotide pyrophosphohydrolase activity, and
- d) an immunogenic fragment of a polypeptide having the amino acid sequence of SEQ ID NO:1.
- 47. (Once Amended) A method for a diagnostic test for a condition or disease associated with the expression of human nucleotide pyrophosphohydrolase-2 in a biological sample, the method comprising:
- a) combining the biological sample with an antibody of claim 46, under conditions suitable for the antibody to bind the polypeptide and form an antibody:polypeptide complex, and
- b) detecting the complex, wherein the presence of the complex correlates with the presence of the polypeptide in the biological sample.

DA

(

Docket No.: PF-0420-2 DIV

- 48. The antibody of claim 46, wherein the antibody is:
- a) a chimeric antibody,
- b) a single chain antibody,
- c) a Fab fragment,
- d) a F(ab')₂ fragment, or
- e) a humanized antibody.
- 49. A composition comprising an antibody of claim 46 and an acceptable excipient.
- D3 51. (Once Amended) A composition of claim 49, further comprising a label.
 - 53. A method of preparing a polyclonal antibody with the specificity of the antibody of claim 46, the method comprising:
 - a) immunizing an animal with a polypeptide having an amino acid sequence of SEQ ID NO:1, or an immunogenic fragment thereof, under conditions to elicit an antibody response,
 - b) isolating antibodies from said animal, and
 - c) screening the isolated antibodies with the polypeptide, thereby identifying a polyclonal antibody which binds specifically to a polypeptide having an amino acid sequence of SEQ ID NO:1.
- 54. (Once Amended) A polyclonal antibody produced by a method of claim 53.
 - 55. A composition comprising the antibody of claim 54 and a suitable carrier.
 - 56. A method of making a monoclonal antibody with the specificity of the antibody of claim 46, the method comprising:
 - a) immunizing an animal with a polypeptide having an amino acid sequence of SEQ ID NO:1, or an immunogenic fragment thereof, under conditions to elicit an antibody response,
 - b) isolating antibody producing cells from the animal,
 - c) fusing the antibody producing cells with immortalized cells to form monoclonal antibody-

Docket No.: PF-0420-2 DIV

producing hybridoma cells,

- d) culturing the hybridoma cells, and
- e) isolating from the culture monoclonal antibody which binds specifically to a polypeptide having an amino acid sequence of SEQ ID NO:1.
 - 57. A monoclonal antibody produced by a method of claim 56.
 - 58. A composition comprising the antibody of claim 57 and a suitable carrier.
- 59. The antibody of claim 46, wherein the antibody is produced by screening a Fab expression library.
- 60. The antibody of claim 46, wherein the antibody is produced by screening a recombinant immunoglobulin library.
- 61. A method of detecting a polypeptide having an amino acid sequence of SEQ ID NO:1 in a sample, the method comprising:
- a) incubating the antibody of claim 46 with a sample under conditions to allow specific binding of the antibody and the polypeptide, and
- b) detecting specific binding, wherein specific binding indicates the presence of a polypeptide having an amino acid sequence of SEQ ID NO:1 in the sample.
- 62. A method of purifying a polypeptide having an amino acid sequence of SEQ ID NO:1 from a sample, the method comprising:
- a) incubating the antibody of claim 46 with a sample under conditions to allow specific binding of the antibody and the polypeptide, and
- b) separating the antibody from the sample and obtaining the purified polypeptide having an amino acid sequence of SEQ ID NO:1.

65. (New) An isolated antibody which specifically binds to a polypeptide comprising the amino acid sequence of SEQ ID NO:1.

66. (New) An isolated antibody of claim 46, which specifically binds to a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to the amino acid sequence of SEQ ID NO:1, wherein the polypeptide has nucleotide pyrophosphohydrolase activity.

- 67. (New) An isolated antibody of claim 46, which specifically binds to a fragment of a polypeptide, wherein the polypeptide consists of the amino acid sequence of SEQ ID NO:1, and wherein the fragment has nucleotide pyrophosphohydrolase activity.
- 68. (New) An isolated antibody of claim 46, which specifically binds to an immunogenic fragment of a polypeptide, wherein the polypeptide consists of the amino acid sequence of SEQ ID NO:1.

105014 6 09/757,716